Advaccine Biopharma 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
INO-4800 / Inovio, The Wistar Institute
ChiCTR2000040146: A Phase II, Randomized, Double-blinded, Placebo-controlled, Dose-finding Clinical Study to Evaluate the Safety and Immunogenicity of Different Doses of INO-4800 Intradermal Injection Followed by Electroporation in Healthy Adult and Elderly Volunteers

Completed
2
640
 
pGX9501 1.0 mg / placebo ;pGX9501 1.0 mg / placebo ;pGX9501 2.0 mg/ placebo ;pGX9501 2.0 mg/ placebo
Jiangsu Provincial Center for Disease Control and Prevention; Advaccine (Suzhou) Biopharmaceutical, Ltd., Sponosor
Novel Coronavirus Pneumonia (COVID-19)
 
 
ChiCTR2000038152: A Single-center, Randomized, Double-blind, Placebo-controlled, Dose Ranging Phase I Study to Evaluate the Safety, Tolerability, and Immunogenicity of INO-4800, Administered Intradermally Followed by Electroporation in Healthy Volunteers

Completed
1
45
 
Vaccine INO-4800 ;placebo
Huashan Hospital Affiliated to Fudan University; Huashan Hospital Affiliated to Fudan University, Sponosor Investment
Novel Coronavirus Pneumonia (COVID-19)
 
 
rRSV-G protein/CsA (BARS13) / Advaccine Biopharma
NCT04681833: Safety and Efficacy of BARS13 in the Elderly

Completed
2
125
RoW
Recombinant Respiratory Syncytial Virus Vaccine (BARS13) /placebo, Recombinant Respiratory Syncytial Virus Vaccine (BARS13), Placebo
Advaccine (Suzhou) Biopharmaceuticals Co., Ltd.
Respiratory Syncytial Virus Infections
01/24
04/24

Download Options